Drug Profile

VERVE 102

Alternative Names: VERVE-102

Latest Information Update: 23 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Verve Therapeutics
Class Antihyperlipidaemics; RNA
Mechanism of Action Gene modulators; PCSK9 protein expression inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I Hyperlipoproteinaemia type IIa

Most Recent Events

17 Jun 2025 VERVE 102 receives fast track status for Hyperlipoproteinaemia type IIa in the US
17 Jun 2025 Verve Therapeutics plans to initiate a phase III trial for Hyperlipoproteinaemia type IIa in the US
30 Apr 2024 Phase-I clinical trials in Hyperlipoproteinaemia type IIa in New Zealand, Australia (IV) (NCT06164730)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com